The company EnteroBiotix has added Dr. Murray Stewart, a well-known medical leader, to its Board of Directors. Dr. Stewart previously served as the Chief Medical Officer (CMO) at GSK, a major pharmaceutical company. He has also held high-level positions at Rhythm Pharmaceuticals and Novelion Therapeutics. With his deep experience in drug development and safety, Dr. Stewart will help guide EnteroBiotix as it works on a new treatment for irritable bowel syndrome with constipation (IBS-C). During his time at GSK, he managed patient safety across all their products, including medicines, vaccines, and consumer health items. He also led important research in areas like heart disease and diabetes. At Rhythm Pharmaceuticals, he played a key role in getting the first approvals in the U.S. and Europe for IMCIVREE®, a medicine for rare genetic obesity conditions. EnteroBiotix is currently running a clinical trial called the RISE study for their investigational oral microbiome therapy, EBX-102-02. This trial is in Phase 2b and will include about 300 patients with moderate to severe IBS-C. The study is designed to test how safe, effective, and tolerable the treatment is compared to a placebo. This trial follows an earlier Phase 2a study, called TrIuMPH, and EnteroBiotix plans to move to Phase 3 trials in the future. Dr. James McIlroy, Founder and CEO of EnteroBiotix, stated, “Dr. Stewart’s experience in turning promising treatments into approved medicines is incredibly valuable as we advance the RISE study and prepare for the next steps in developing EBX-102-02.”